BioCryst Pharmaceuticals Inc (STU:BO1)

€ 7.362 -0.256 (-3.36%) Market Cap: 1.52 Bil Enterprise Value: 1.97 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call Transcript

Nov 04, 2024 / 01:30PM GMT

Release Date Price: €7.72 (+1.66%)

Transcript 10-Q8-K

Key Points

Positve

BioCryst Pharmaceuticals Inc (BCRX) reported a nearly 36% year-over-year growth in ORLADEYO revenue, highlighting strong market performance.
The company is advancing BCX17725 for Netherton syndrome into clinical trials, addressing an unmet medical need.
BioCryst Pharmaceuticals Inc (BCRX) achieved an operating profit for the quarter, excluding non-cash stock compensation.
The company is on track to submit regulatory submissions for the first oral prophylactic therapy for children with HAE in 2025.
BioCryst Pharmaceuticals Inc (BCRX) has a strong cash position and expects to achieve sustained profitability and positive cash flow in the near future.

Negative

The company faces challenges in transitioning patients from free drug to commercial paid therapy, particularly in the Medicare segment.
There is uncertainty regarding the impact of new injectable prophylactic therapies entering the market in 2025.
Operating expenses are expected to increase due to costs associated with advancing clinical trials and supporting the HAE community.
The company anticipates cash flow negativity in Q4 and Q1, despite overall positive financial performance.
BioCryst Pharmaceuticals Inc (BCRX) faces potential challenges in achieving its long-term goal of 85% paid therapy rate, particularly with Medicare patients.

Operator

Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. (Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to John Bluth, Chief Communications Officer. Please go ahead.

John Bluth

BioCryst Pharmaceuticals Inc - IR Contact Officer

Thanks, Dave. Good morning and welcome to BioCryst Third Quarter 2024 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray; and Chief Data and Insights Officer, Jinky Rosselli. Following our remarks, we'll answer your questions.

Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.